Eslicarbazepine acetate (Zebinix^®), a voltage-gated sodium channel blocker, is a once-daily, orally administered anti-seizure medication available in the EU for use as monotherapy in adults with newly diagnosed focal-onset seizures and as adjunctive therapy in adults, adolescents and children aged > 6 years with focal-onset seizures. In adult patients, adjunctive eslicarbazepine acetate was generally associated with a significant decrease in seizure frequency and an increase in responder rate compared with placebo. The drug was also an effective monotherapy agent in adult patients, demonstrating noninferiority to controlled-release carbamazepine, in terms of seizure freedom rates. In paediatric patients, eslicarbazepine acetate provided seizure control when administered as adjunctive therapy, with the benefits appearing to be dependent on age and dose. The antiepileptic efficacy of eslicarbazepine acetate as adjunctive therapy or as monotherapy was maintained during longer-term extension studies, with each extension study period being up to 2 years. Oral eslicarbazepine acetate was generally well tolerated when administered as adjunctive therapy or monotherapy in adult patients and when administered as adjunctive therapy in paediatric patients, with most adverse events being of mild or moderate intensity. In conclusion, with the convenience of once-daily administration, eslicarbazepine acetate is an effective and generally well-tolerated treatment option for adults, adolescents and children aged > 6 years with focal-onset seizures.

醋酸艾司利卡西平 (Zebinix ^®)，一种电压门控钠通道阻滞剂，是一种每日一次、口服给药的抗癫痫药物，在欧盟有售，可用作新诊断的局灶性癫痫发作的成人的单一疗法，以及成人、青少年和老年儿童的辅助疗法> 6 年有局灶性癫痫发作。在成年患者中，与安慰剂相比，辅助性醋酸艾司利卡西平通常与癫痫发作频率显着降低和反应率增加有关。该药物还是成人患者的有效单药治疗药物，在无癫痫发作率方面表现出不劣于控释卡马西平。在儿科患者中，醋酸艾司利卡西平作为辅助治疗给药时可控制癫痫发作，其益处似乎取决于年龄和剂量。在长期扩展研究期间，醋酸艾司利卡西平作为辅助治疗或单药治疗的抗癫痫疗效保持不变，每个扩展研究期长达 2 年。在成人患者中作为辅助治疗或单药治疗以及在儿科患者中作为辅助治疗给药时，口服醋酸艾斯利卡西平通常耐受性良好，大多数不良事件为轻度或中度。总之，由于每天给药一次的便利性，醋酸艾司利卡西平是一种有效且普遍耐受性良好的治疗选择，适用于患有局灶性癫痫发作的成人、青少年和 6 岁以上儿童。每个扩展学习期最长为2年。在成人患者中作为辅助治疗或单药治疗以及在儿科患者中作为辅助治疗给药时，口服醋酸艾斯利卡西平通常耐受性良好，大多数不良事件为轻度或中度。总之，由于每天给药一次的便利性，醋酸艾司利卡西平是一种有效且普遍耐受性良好的治疗选择，适用于患有局灶性癫痫发作的成人、青少年和 6 岁以上儿童。每个扩展学习期最长为2年。在成人患者中作为辅助治疗或单药治疗以及在儿科患者中作为辅助治疗给药时，口服醋酸艾斯利卡西平通常耐受性良好，大多数不良事件为轻度或中度。总之，由于每天给药一次的便利性，醋酸艾司利卡西平是一种有效且普遍耐受性良好的治疗选择，适用于患有局灶性癫痫发作的成人、青少年和 6 岁以上儿童。